CVKD CADRENAL THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CADRENAL THERAPEUTICS INC reported revenue of n/a, net income of −$3.32M and diluted EPS of −$1.14; for the fiscal year ended December 2025 revenue was n/a.
CVKD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$13.5M, net income −$13.2M (margin n/a), EPS −$6.64
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$11.0M, net income −$10.7M (margin n/a), EPS −$8.73
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$7.63M, net income −$8.36M (margin n/a), EPS −$9.29
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$2.70M, net income −$6.71M (margin n/a), EPS −$0.85
CVKD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.32M, EPS −$1.14
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.50M, EPS −$1.04
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.04M, EPS −$1.37
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.69M, EPS −$1.31
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.67M, EPS −$1.87
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.85M, EPS −$2.09
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$4.19M, EPS −$2.75
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.41M, EPS −$2.18
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.39M, EPS −$2.24
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.66M, EPS −$1.56
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.14M, EPS −$7.71
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.04M, EPS −$1.01
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.00M, EPS −$0.09
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.17M, EPS −$0.48
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.01M, EPS −$0.77
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.03M, EPS −$0.13
- Quarter ended Jun 30, 2022: revenue n/a, net income −$502K, EPS $0.07
- Quarter ended Mar 31, 2022: revenue n/a, net income −$177K, EPS −$0.02
CVKD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.6M, share buybacks n/a, dividends $16.50 per share
- Fiscal year ended Dec 2024: operating cash flow −$7.36M, share buybacks n/a, dividends $16.50 per share
- Fiscal year ended Dec 2023: operating cash flow −$3.53M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.20M, share buybacks n/a
CVKD balance sheet
- Jun 30, 2026: cash $2.39M, total assets $5.59M, total liabilities $1.50M, shareholders' equity $4.09M
- Mar 31, 2026: cash $2.31M, total assets $2.86M, total liabilities $1.06M, shareholders' equity $1.80M
- Dec 31, 2025: cash $4.01M, total assets $4.33M, total liabilities $1.59M, shareholders' equity $2.74M
- Sep 30, 2025: cash $3.86M, total assets $4.09M, total liabilities $1.35M, shareholders' equity $2.73M
- Jun 30, 2025: cash $5.57M, total assets $5.98M, total liabilities $1.68M, shareholders' equity $4.30M
- Mar 31, 2025: cash $7.34M, total assets $7.95M, total liabilities $1.84M, shareholders' equity $6.11M
- Dec 31, 2024: cash $10.0M, total assets $10.1M, total liabilities $2.68M, shareholders' equity $7.44M
- Sep 30, 2024: cash $4.36M, total assets $4.68M, total liabilities $1.27M, shareholders' equity $3.41M
Is CVKD profitable?
No. CADRENAL THERAPEUTICS INC lost $11.5M over the last four quarters.
What is CVKD's EPS?
Diluted earnings per share over the last four quarters were −$4.86; −$1.14 in the latest quarter.
Does CVKD pay a dividend?
CADRENAL THERAPEUTICS INC paid $16.50 per share in dividends in the fiscal year ended December 2025.